Angiotensin II receptor 1 type polypeptide-vector vaccine and application thereof

An angiotensin, carrier vaccine technology, applied in cardiovascular system diseases, antibody medical ingredients, medical preparations with non-active ingredients, etc. Poor treatment compliance and other problems, to achieve good target organ protection and lower blood pressure

Active Publication Date: 2013-03-27
WUHAN HUAJIYUAN BIOTECH DEV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the above-mentioned renin inhibitors, ACEI and ARB all need to be taken daily, and it is long-term or even life-long. The overall economic burden is heavy, and the adverse reactions of the drugs themselves lead to poor treatment compliance of hypertensive patients. And the target organ protection effect also failed to achieve the maximum effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Angiotensin II receptor 1 type polypeptide-vector vaccine and application thereof
  • Angiotensin II receptor 1 type polypeptide-vector vaccine and application thereof
  • Angiotensin II receptor 1 type polypeptide-vector vaccine and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment example 1

[0033] Implementation case 1 Preparation and identification of ATRQβ-001 vaccine

[0034] The short peptide CGGAFHYESQ was directly synthesized by Shanghai Jier Biochemical Co., Ltd., with a purity of 95%.

[0035] The vector Qβ-2aa virus-like particles was constructed, expressed and purified by our laboratory, with a purity of more than 90%, and it was prepared as follows:

[0036] 1) After mutating the stop codon of the CP protein gene of Qβ phage from TGA to a strong stop codon TAA, clone it into the prokaryotic expression vector pET28a(+) to obtain the pETQβ-CP encoding the CP protein;

[0037] 2) In the Qβ phage CP extension protein gene encoding the position of the immunodominance determining region, that is, between the 72 to 73 codons of the Qβ phage CP extension protein gene, insert the nucleotides AAGCTT encoding lysine and leucine, and The stop codon of the CP protein gene was mutated from TGA to GGA and then cloned into the prokaryotic expression vector PGEX4T-2 to obtain ...

Embodiment example 2

[0048] Implementation case 2 Anti-ATRQβ-001 vaccine short peptide antibody titer

[0049] The male spontaneously hypertensive rats came from Shanghai Slack Experimental Animal Center, and the animals were raised in the SPF Animal Experimental Center of Tongji Medical College, using 12h / 12h light and unrestricted ordinary diet. Specifically divided into 4 groups: ATRQβ-001 vaccine immune group; Ang II-Qβ vaccine immune group (Ang II derivative and Qβ-2aa virus-like particle coupling vaccine); Valsartan drug (Novartis, Switzerland) intragastric administration group; PBS control SHR group. Except for the valsartan intragastric administration group, which was 8 weeks old, the rest groups were all 6-week-old male SHR rats, with 9 rats in each group.

[0050] Take an equal volume of vaccine (not enough to make up with PBS) and PBS, and inject it under the skin at 3-4 points on the back of the rat, 400ul / mouse, the vaccine dose of the vaccine group is about 300ug / mouse, boost twice every...

Embodiment example 3

[0051] Implementation case 3 Specificity of short peptide antibody of anti-ATRQβ-001 vaccine

[0052] The ATRQβ-001 vaccine anti-peptide antibody CQ-8 was purified, and the specificity of the ATRQβ-001 anti-peptide antibody CQ-8 was identified by western blotting and cell immunofluorescence. Set up three groups: CQ-8 is the anti-peptide antibody after ATRQβ-001 vaccine immunized animals, DCQ-8 is the mixture after CQ-8 is neutralized by ATR-001 short peptide, and CON is the negative control antibody. The total protein of SD rat mesenteric tertiary arterial smooth muscle cells was extracted and subjected to immunoblotting analysis. The results showed that CQ-8 can bind to the 41kDa protein in the total protein extract. This protein has a molecular weight of about the rat AT1A receptor. 41kDa) consistent ( image 3 A). At the same time, it was found through cellular immunofluorescence that CQ-8 can bind to the AT1A receptor on the surface of rat mesenteric tertiary arterial smooth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an angiotensin II receptor 1 type polypeptide-vector vaccine and an application thereof, belonging to the field of biotechnology drugs and biologic therapeutics. An angiotensin II receptor 1 type immunogenic peptide containing a first connection locus, a derivant thereof and one or more of carriers are preferably coupled and connected with recombined Qbeta-2aa bacteriophage viruslike particle protein to form an ordered and repeated polypeptide-carrier vaccine. The invention also discloses an application of the vaccine on the aspect of treating primary hypertension. Thevaccine can generate one section of efficient specific immunogenic peptide resisting human angiotensin II receptor 1 type and the antibody of the derivant thereof. RAS (Renin-Angiotensin System) can be effectively prevented from activating, the blood pressure of spontaneously hypertensive rats can be obviously lowered, and the vector vaccine has good function on protecting target organs.

Description

Invention field [0001] The invention belongs to the field of biotechnology medicines and biotherapeutics, and specifically relates to an immunogenic peptide of angiotensin II receptor type 1 (AT1R) and its derivatives, and a carrier, especially virus-like particles (VLP) The polypeptide-carrier vaccine prepared after coupling and the role of the vaccine in treating essential hypertension. Background of the invention [0002] Hypertension is a worldwide problem that seriously endangers human health. The prevalence rate of hypertension in China is 18.8% (2002). There are currently nearly 200 million hypertensive patients nationwide. Hypertension is a major risk factor for cardiovascular and cerebrovascular diseases. The incidence of stroke in China is about 250 / 100,000, and the incidence of coronary heart disease is about 50 / 100,000. Active control of hypertension is an important measure to prevent stroke and coronary heart disease. At present, the treatment control rate of outpat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/48A61K39/00A61P9/12
Inventor 廖玉华周子华陈霄邱志华杨仕俊陈芬王敏余淼
Owner WUHAN HUAJIYUAN BIOTECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap